Table 5.

Most Common Unsolicited Adverse Events for the Overall Vaccination Period (Full Analysis Set).

Preferred Term	Lot Group 1 (N = 377) n (%) [events]	Lot Group 2 (N = 375) n (%) [events]	Lot Group 3 (N = 377) n (%) [events]	Overall (N = 1129) n (%) [events]
Upper respiratory tract infection	19 (5.0) [19]	25 (6.7) [26]	21 (5.6) [23]	65 (5.8) [68]
Injection site nodule	11 (2.9) [11]	10 (2.7) [10]	12 (3.2) [12]	33 (2.9) [33]
Blood potassium increased	6 (1.6) [6]	11 (2.9) [11]	10 (2.7) [10]	27 (2.4) [27]
Injection site discoloration	3 (0.8) [3]	5 (1.3) [5]	7 (1.9) [7]	15 (1.3) [15]
Injection site bruising	5 (1.3) [5]	4 (1.1) [4]	3 (0.8) [3]	12 (1.1) [12]
Urinary tract infection	1 (0.3) [1]	4 (1.1) [4]	4 (1.1) [4]	9 (0.8) [9]
Vaccination site bruising	2 (0.5) [2]	3 (0.8) [4]	2 (0.5) [2]	7 (0.6) [8]
Anxiety	2 (0.5) [2]	2 (0.5) [2]	2 (0.5) [3]	6 (0.5) [7]
Ligament sprain	4 (1.1) [4]	1 (0.3) [1]	1 (0.3) [1]	6 (0.5) [6]
Pyrexia	0	3 (0.8) [3]	3 (0.8) [3]	6 (0.5) [6]

Abbreviations: N = number of subjects in the specified group; n = number of subjects reporting an adverse event in the specified Preferred Term category.